Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 VirusesArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Abbott Abbott SARS-CoV-2 IgG acute respiratory syndrome Analysis approach authorization BAU Beta binding antibody unit Canada CCP characterized Chicago Chicago IL clinical trial convalescent convalescent plasma coronavirus COVID-19 COVID-19 convalescent plasma Cutoff Delta disease course drug Emergency EUA evaluated Evidence experiment FDA food Gamma highest hospitalized patient Humoral immunity identify IgG immune IMPROVE Mann-Whitney U method comparisons Neutralization assay Neutralizing neutralizing antibody outcome Patient patient group plaque reduction neutralization plaque reduction neutralization. plasma PRNT quantitative determination required SARS-CoV-2 SARS-CoV-2 antibody selected significantly specimen tested the SARS-CoV-2 time-consuming treat United State utilization variant VLP VoC wild-type with COVID-19 [DOI] 10.1128/spectrum.02811-22 PMC 바로가기
Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron VariantArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition Affect analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibodies antibody antibody assay Antibody assays antigenic antigenic structure antigens assays change changes in characterized controls convalescent individual correlation diagnostic immunoassay immunoassays immunoreactivity impairing individual Infection lack neutralization Neutralization assay Neutralizing activity Neutralizing antibodies Neutralizing antibody titer omicron Primary infection Protein quantified RBD reduced SARS-CoV-2 SARS-CoV-2-specific antibody sensitivity significantly spike statistically significant reduction subjects surrogate assay. tested the SARS-CoV-2 the Spike variant variants were used wild type wild-type wild-type strain [DOI] 10.1128/spectrum.02129-22 PMC 바로가기
Priming conditions shape breadth of neutralizing antibody responses to sarbecovirusesArticle Published on 2022-10-212022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] BNT162b2 BNT162b2 vaccine breadth Breakthrough infection Cohort Combination condition cross-neutralization cross-protective dose elicit highest immunized inactivated include individual Infection magnitude mRNA multiplex neutralization Neutralization assay neutralizing antibody Neutralizing antibody response of BNT162b2 omicron public health Receptor binding domain sarbecovirus Sarbecoviruses SARS-CoV-1 SARS-CoV-1 infection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant sera Sinopharm vaccination Vaccine Vaccine design Virus spike viruses [DOI] 10.1038/s41467-022-34038-6 PMC 바로가기
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants중증급성호흡기증후군 코로나바이러스 2 델타 및 오미크론 변이체에 대한 단일클론항체의 임상적 효능 및 시험관내 중화능Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Casirivimab casirivimab/imdevimab clinical Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient decrease delta variant dosage Efficacy except for exhibit Hospital stay Imdevimab in vitro in vitro data in vivo Infection mAb mAbs monoclonal monoclonal antibodies monoclonal antibody neutralization Neutralization assay neutralization capacity neutralizing capacity neutralizing effect Omicron variant Patient patients treated performed provided receiving respiratory respiratory tract respiratory viral RNA SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus sotromivab Sotrovimab the SARS-CoV-2 therapeutic therapy treated variant Viral Virus neutralization virus neutralization assay virus neutralization assays [DOI] 10.1002/jmv.27916 PMC 바로가기 [Article Type] Article
Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 InfectionArticle Published on 2022-09-282022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome Antibody Response Antibody titer B.1.1.529 B.1.1.7 B.1.167.2 binding activity circulating variant coronavirus coronavirus 2 coronavirus disease COVID-19 cytopathic delta variant domain ELISA enzyme-linked immunosorbent assays humoral IgA IgG IgG antibody IgM immune Immunity Immunoglobulin Infection Live virus median Mild Month Neutralization assay Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer P.1 Patient persistent Protein RBD RBD protein respiratory response SARS-CoV-2 SARS-CoV-2 antigen SARS-COV-2 infection SARS-CoV-2 variant serological response serum antibody serum sample variant virus was reduced were measured wild-type wild-type SARS-CoV-2 Wuhan-1 [DOI] 10.1093/infdis/jiac099 PMC 바로가기
Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assayArticle Published on 2022-09-262022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] Ad26.COV2.S Affect analyzed anti-SARS-CoV-2 AZD1222 B.1.1.529 B.1.617.2 booster dose booster vaccination BSL-2 collected Comparative analysis condition controls convalescent correlated COVID-19 Delta Efficacy elicited emergence gold standard help helping Immune status immunogenicity individual Infection live viruses management MNT mRNA mRNA-1273 NAb neutralization neutralization activity Neutralization assay neutralize Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody omicron performance pseudotyped Pseudotyped virus receiving reduced reduction reliability SARS-CoV-2 SARS-CoV-2 spike protein second dose sera strain vaccination Vaccination strategies Vaccine vaccinee Vaccines variant variants of concern variants of SARS-CoV-2 Viral vector virus VoC VOCs were used wild type WT strain Wuhan-Hu-1 [DOI] 10.3389/fimmu.2022.981693 PMC 바로가기
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinctArticle Published on 2022-09-232022-11-15 Journal: Science Immunology [Category] SARS, 변종, 진단, [키워드] Affect antigenic Antisera Beta booster Calu-3 Calu-3 cell cell line Characteristics Cluster Clustering Delta Efficacy Gamma Genetic human airway Map Neutralization assay not affect omicron outliers Primary infection replacing reveal SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sequence spike mutations Spread Topology Vaccine vaccine-induced antibody response Vaccines variant viruses [DOI] 10.1126/sciimmunol.abq4450 PMC 바로가기
Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2Article Published on 2022-09-162022-11-15 Journal: Viruses [Category] SARS, 진단, [키워드] ACE2 ACE2 binding ACE2 expression Affect antibodies antibody Cell cell receptor domain Effectiveness expression Infection lentivirus Level monoclonal monoclonal antibody N-terminal domain neutralization Neutralization assay neutralize Neutralizing activity neutralizing antibody neutralizing antibody epitopes NTD polyclonal antibody polyclonal human sera pseudovirus Pseudovirus neutralization assays RBD Region SARS-CoV-2 Serum Neutralization spike epitope subset target target cell target cell receptor expression. target cells the RBD therapeutic [DOI] 10.3390/v14092061 PMC 바로가기
Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessmentArticle Published on 2022-09-152022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, 치료제, [키워드] anti-N antibody anti-S anti-S antibody Anti-SARS-CoV-2 S antiviral therapy can be used Cancer patients comparable correlated correlation COVID-19 Critical Elecsys® Anti-SARS-CoV-2 S evaluate expected Follow-up group Immune status immunoassay immunosuppressed patients in both groups linear Mild moderate Neutralization antibody Neutralization assay Neutralizing activity neutralizing antibody onset of symptom Patient patients patients with COVID-19 performance positive predict produced Proteins Roche SARS-CoV-2 neutralizing antibody serum serum sample significantly higher vaccine response Virus neutralization [DOI] 10.1371/journal.pone.0274181 PMC 바로가기
SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protectionComirnaty® COVID-19 백신의 동종 3차 접종 후 요양원 거주자의 SARS-CoV-2 Omicron BA.1 변이형 돌발성 감염: 보호 상관 관계 찾기Observational Study Published on 2022-09-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료제, [키워드] anti-RBD Anti-spike anti-spike antibodies antibody blood levels booster dose both groups Breakthrough infection CD4 CD8 chemiluminescent immunoassay Comirnaty® COVID-19 vaccine comparable COVID-19 COVID-19 vaccine cytokine detectable dose evaluated female flow cytometry Frequency homologous immune parameter Immunological response in both groups individual level Infection intracellular cytokine staining investigated likelihood median median age Neutralization assay Neutralizing Neutralizing antibodies neutralizing antibody not correlated nursing home nursing home residents observational study omicron Omicron variant participant Peripheral blood predict Pseudotyped virus quantified reactive Receptor binding domain risk SARS-CoV-2 SARS-CoV-2 Omicron variant SARS-CoV-2 spike SARS-CoV-2-S spike spike-reactive T cells. subsequent symptomatic T cell T cells total antibody uninfected participant Vaccine variant were measured [DOI] 10.1002/jmv.27867 PMC 바로가기 [Article Type] Observational Study